A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
← catalyst calendarNCT07662057 · readout ≤ 133 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
130estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: AB102
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants experiencing Adverse Events (AEs)
measured Up to 49 days
Maximum observed plasma concentration (Cmax) for SAD and MAD Parts
measured Up to 28 days
Time to attain maximum observed plasma concentration (tmax) for SAD and MAD Parts
measured Up to 28 days
Terminal elimination half-life (t1/2) for SAD Part
measured Up to 28 days
Area under the plasma concentration-time curve from time 0 to last sample (AUClast) for SAD and MAD Parts
measured Up to 28 days
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24h) for SAD Part
measured Up to 28 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for SAD Part
measured Up to 28 days
Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) for MAD Part
measured Up to 28 days
Accumulation ratio (Racc(Cmax))for MAD Part
measured Up to 28 days
Accumulation ratio(Racc(AUCtau)) for MAD Part
measured Up to 28 days
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed